XOMA Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
35,451.00
18,866.00
55,447.00
5,564.00
52,690.00
5,299
SG&A Expense
90,753.00
98,758.00
89,940.00
61,787.00
31,908.00
20,215
EBIT
57,877.00
81,748.00
36,025.00
56,992.00
20,478.00
14,946
Unusual Expense
61,494.00
45,334.00
13,678.00
5,727.00
4,097.00
2,474
Non Operating Income/Expense
70.00
2,416.00
5,506.00
1,681.00
1,115.00
4,901
Interest Expense
4,631.00
4,303.00
3,765.00
3,946.00
1,238.00
922
Pretax Income
124,072.00
38,301.00
20,606.00
53,530.00
16,258.00
13,441
Income Tax
14.00
-
-
-
1,662.00
98
Consolidated Net Income
124,058.00
38,301.00
20,606.00
53,530.00
11,317.00
13,343
Net Income
124,058.00
38,301.00
20,606.00
53,530.00
11,317.00
13,343
Net Income After Extraordinaries
124,058.00
38,301.00
20,606.00
53,530.00
11,317.00
13,343
Net Income Available to Common
124,058.00
38,301.00
20,606.00
53,530.00
5,714.00
13,343
EPS (Basic)
28.60
13.40
3.40
8.89
0.73
1.59
Basic Shares Outstanding
4,346.90
5,371.80
5,890.20
6,021.00
7,619.00
8,373
EPS (Diluted)
28.54
13.49
3.50
8.89
0.73
1.59
Diluted Shares Outstanding
4,346.90
5,766.70
5,890.20
6,021.00
7,980.00
8,373
EBITDA
55,302.00
79,892.00
34,493.00
56,223.00
20,782.00
14,916
Other After Tax Income (Expense)
-
-
-
-
3,279.00
-
Preferred Dividends
-
-
-
-
5,603.00
-

About XOMA

View Profile
Address
2200 Powell Street
Emeryville California 94608
United States
Employees -
Website http://www.xoma.com
Updated 07/08/2019
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J.